title: [Changes in IGFBP-3 in relation to administration of rGH to deficient children].
abstract: Serum IGFBP3 levels were tested in 7 GHD children before the rGH therapy, at the end of the same therapy and 1, 2, 4, and 8 weeks later. The IGFBP3 concentration returned to the pre-therapy levels only 6 weeks after the end of the therapy.
authors.affiliation: Istituto di Pediatria, Università di Perugia, Italia.
authors.forename: M
authors.initials: M
authors.lastname: Sposito
authors.forename: F
authors.initials: F
authors.lastname: Truffarelli
authors.forename: G
authors.initials: G
authors.lastname: De Giorgi
authors.forename: I
authors.initials: I
authors.lastname: Sabalich
authors.forename: R
authors.initials: R
authors.lastname: Britta
authors.forename: L
authors.initials: L
authors.lastname: Cova
authors.forename: S
authors.initials: S
authors.lastname: Rufini
mesh_terms: D002352:Carrier Proteins / Q000097:blood*; D002648:Child; D002675:Child, Preschool; D005260:Female; D005500:Follow-Up Studies; D006130:Growth Disorders / Q000188:drug therapy*; D013006:Growth Hormone / Q000008:administration & dosage* / Q000172:deficiency; D006131:Growth Inhibitors / Q000097:blood*; D006801:Humans; D018969:Insulin-Like Growth Factor Binding Proteins; D008297:Male; D011863:Radioimmunoassay; D011994:Recombinant Proteins / Q000008:administration & dosage; D013002:Somatomedins / Q000032:analysis*; D013997:Time Factors
chemical_list: D002352:Carrier Proteins; D006131:Growth Inhibitors; D018969:Insulin-Like Growth Factor Binding Proteins; D011994:Recombinant Proteins; D013002:Somatomedins; D013006:Growth Hormone